Locally Advanced Rectal Carcinoma Clinical Trial
Official title:
Novel Imaging of Lymph Nodes in Patients With Rectal Cancer Using Ferumoxytol Enhanced MRI
This pilot clinical trial studies how well ferumoxytol-enhanced magnetic resonance imaging (MRI) works in imaging lymph nodes in patients with rectal cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced). Ferumoxytol is a form of very small iron particles that are taken up by cells in normal lymph nodes and may work better in imaging patients with rectal cancer when given with MRI.
PRIMARY OBJECTIVE: I. To determine feasibility of administering ferumoxytol and obtaining ferumoxytol enhanced magnetic resonance (MR) images in patients with resectable locally advanced rectal cancer with enlarged or suspicious lateral pelvic lymph nodes before starting neoadjuvant therapy and again before total mesorectal excision. SECONDARY OBJECTIVES: I. To collect detailed information about the location of ultrasmall superparamagnetic iron oxide (USPIO)-MRI detected lymph nodes prior to neoadjuvant therapy and again prior to total mesorectal excision. II. To compare the sensitivity and specificity of ferumoxytol enhanced MR imaging in assessment of pathological lymph nodes with those of non-USPIO-MRI and positron emission tomography-computed tomography (PET-CT). OUTLINE: Patients receive ferumoxytol intravenously (IV) over 15 minutes and then after 24-36 hours undergo ferumoxytol-enhanced MRI before start of neoadjuvant therapy and within 4 weeks before surgery. After completion of study treatment, patients are followed up for 4-6 weeks. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05920928 -
Comparison of the Clinical Response of Total Neoadjuvant Treatment of Two Methods of Long-term or Short-term Chemoradiotherapy in Rectal Cancer
|
N/A | |
| Completed |
NCT06314737 -
Assessment of Efficacy of Neoadjuvant Therapy in Locally Advanced Rectal Cancer
|
||
| Recruiting |
NCT05524012 -
Longitudinal Multimodal Response Assessment During Neoadjuvant Treatment of Rectal Cancer
|
||
| Recruiting |
NCT05601505 -
Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer
|
Phase 2 | |
| Recruiting |
NCT05876026 -
MRI T1 Relaxation Time in Rectal Cancer
|
||
| Completed |
NCT05622357 -
Prospective Study of Short Course Radiation Therapy Followed by Neoadjuvant Chemotherapy and Surgery in Locally Advanced Rectal Cancer
|
Phase 2 | |
| Terminated |
NCT04406857 -
Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) During Radiation Therapy for Rectal Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT06292975 -
Exercise for Improving Radiotherapy Efficacy in Rectal Cancer
|
N/A | |
| Not yet recruiting |
NCT06276686 -
Exercise for Improving Long-course Chemoradiotherapy Efficacy in People With Locally Advanced Rectal Cancer
|
N/A | |
| Recruiting |
NCT05591534 -
Endorectal Brachytherapy for Rectal Cancer
|
Phase 2 | |
| Recruiting |
NCT05722288 -
Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers
|
Phase 2 | |
| Not yet recruiting |
NCT05645094 -
Neoadjuvant Envafolimab in Resectable and Locally Advanced MSI-H/dMMR Rectal Cancer
|
||
| Active, not recruiting |
NCT06314750 -
Deep Learning Based MRI Radiomics in Predicting the Clinical Risk of Locally Advanced Rectal Cancer
|
||
| Recruiting |
NCT05731726 -
Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer
|
Phase 2 | |
| Recruiting |
NCT06312982 -
A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer: From a Multicenter Phase II Cohort to a Phase III Randomized Controlled Study
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04703101 -
Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer
|
Phase 1 | |
| Recruiting |
NCT05610163 -
Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation
|
Phase 2 | |
| Recruiting |
NCT05245786 -
An Investigational Scan (64Cu-Labeled M5A Antibody) in Combination With SOC Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer
|
Early Phase 1 | |
| Recruiting |
NCT05772923 -
Organ Preservation in Rectal Cancer: Contact X-ray Brachytherapy vs Extending the Waiting Interval and Local Excision
|
N/A | |
| Recruiting |
NCT05792735 -
Neoadjuvant Cadonilimab Plus Chemotherapy Following Short-Course Radiotherapy in Locally Advanced Rectal Cancer
|
Phase 2 |